Key facts
- 52-week range (closes)
- $62.03 – $90.86 Lowest close Oct 16, 2025, highest Sep 3, 2026; 251 daily closes to Oct 13, 2026 from Dalsna Finance's price archive
- Fiscal year ends
- December Fiscal 2025 ended Dec 27, 2025, from SEC filings
- In the S&P 500 since
- Mar 18, 2015, replacing Carefusion (CFN) · Carefusion was acquired by Becton Dickinson. · All S&P 500 changes
Henry Schein (HSIC) is trading up at $85.03 (+1.26%) on NYSE/NASDAQ, as of the latest quote. It is a S&P 500 constituent in the Health Care sector.
Henry Schein revenue & net income history (FY2016–FY2025)
| FY2016Dec 2016 | FY2017Dec 2017 | FY2018Dec 2018 | FY2019Dec 2019 | FY2020Dec 2020 | FY2021Dec 2021 | FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | $11.6B | $12.5B | $13.2B | $9.99B | $10.1B | $12.4B | $12.6B | $12.3B | $12.7B | $13.2B |
| Growth (year over year) | +8.9% | +7.7% | +5.9% | −24.4% | +1.3% | +22.6% | +2.0% | −2.4% | +2.7% | +4.0% |
| Gross profit | $3.23B | $2.75B | $2.91B | $3.09B | $2.82B | $3.67B | $3.83B | $3.86B | $4.02B | $4.11B |
| Gross margin | 27.9% | 22.0% | 22.0% | 31.0% | 27.8% | 29.6% | 30.3% | 31.3% | 31.7% | 31.1% |
| Operating income | $771.6M | $669.8M | $600.6M | $718.3M | $535.0M | $852.0M | $747.0M | $615.0M | $621.0M | $653.0M |
| Operating margin | 6.7% | 5.4% | 4.5% | 7.2% | 5.3% | 6.9% | 5.9% | 5.0% | 4.9% | 5.0% |
| Net income | $506.8M | $406.3M | $535.9M | $694.7M | $404.0M | $631.0M | $538.0M | $416.0M | $390.0M | $398.0M |
| Net margin | 4.4% | 3.3% | 4.1% | 7.0% | 4.0% | 5.1% | 4.3% | 3.4% | 3.1% | 3.0% |
| EPS (diluted) | $3.10 | $2.57 | $3.49 | $4.65 | $2.82 | $4.45 | $3.91 | $3.16 | $3.05 | $3.27 |
| Balance sheet | ||||||||||
| Cash and equivalents | $62.4M | $158.0M | $56.9M | $106.1M | $421.0M | $118.0M | $117.0M | $171.0M | $122.0M | $156.0M |
| Total assets | $6.81B | $7.86B | $8.50B | $7.15B | $7.77B | $8.48B | $8.61B | $10.6B | $10.2B | $11.2B |
| Total liabilities | $3.35B | $4.21B | $4.65B | $3.23B | $3.46B | $3.81B | $3.94B | $5.42B | $5.38B | $6.42B |
| Long-term debt | $715.5M | $907.8M | $980.3M | $622.9M | $515.8M | $811.0M | $1.04B | $1.94B | $1.83B | $2.31B |
| Shareholders' equity | $2.79B | $2.81B | $2.96B | $3.00B | $3.35B | $3.42B | $3.45B | $3.65B | $3.39B | $3.25B |
| Cash flow | ||||||||||
| Operating cash flow | $642.6M | $545.5M | $684.7M | $654.1M | $599.0M | $710.0M | $602.0M | $500.0M | $848.0M | $712.0M |
| Capital expenditure | $70.2M | $62.4M | $71.3M | $76.2M | $49.0M | $79.0M | $96.0M | $147.0M | $148.0M | $139.0M |
| Free cash flow | $572.4M | $483.1M | $613.4M | $577.9M | $550.0M | $631.0M | $506.0M | $353.0M | $700.0M | $573.0M |
| Share buybacks | $550.0M | $450.0M | $200.0M | $525.0M | $74.0M | $401.0M | $485.0M | $250.0M | $385.0M | $850.0M |
| Q3 FY24Sep 2024 | Q4 FY24†Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25†Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $3.17B | $3.19B | $3.17B | $3.24B | $3.34B | $3.44B | $3.37B | $3.46B |
| Growth (year over year) | +0.4% | +5.8% | −0.1% | +3.3% | +5.2% | +7.7% | +6.3% | +6.7% |
| Gross profit | $993.0M | $993.0M | $1.00B | $1.02B | $1.03B | $1.06B | $1.07B | $1.10B |
| Gross margin | 31.3% | 31.1% | 31.6% | 31.4% | 30.7% | 30.9% | 31.8% | 31.8% |
| Operating income | $157.0M | $155.0M | $175.0M | $151.0M | $164.0M | $163.0M | $182.0M | $171.0M |
| Operating margin | 4.9% | 4.9% | 5.5% | 4.7% | 4.9% | 4.7% | 5.4% | 4.9% |
| Net income | $99.0M | $94.0M | $110.0M | $86.0M | $101.0M | $101.0M | $107.0M | $94.0M |
| Net margin | 3.1% | 2.9% | 3.5% | 2.7% | 3.0% | 2.9% | 3.2% | 2.7% |
| EPS (diluted) | $0.78 | $0.75 | $0.88 | $0.70 | $0.84 | $0.85 | $0.92 | $0.82 |
| Balance sheet | ||||||||
| Cash and equivalents | $126.0M | $122.0M | $127.0M | $145.0M | $136.0M | $156.0M | $138.0M | $157.0M |
| Total assets | $10.6B | $10.2B | $10.5B | $10.9B | $11.1B | $11.2B | $11.3B | $11.4B |
| Total liabilities | $5.63B | $5.38B | $5.76B | $6.01B | $6.20B | $6.42B | $6.48B | $6.66B |
| Long-term debt | $1.91B | $1.83B | $1.97B | $2.09B | $2.15B | $2.31B | $2.33B | $2.30B |
| Shareholders' equity | $3.50B | $3.39B | $3.31B | $3.44B | $3.36B | $3.25B | $3.27B | $3.16B |
| Cash flow | ||||||||
| Operating cash flow | $151.0M | $204.0M | $37.0M | $120.0M | $174.0M | $381.0M | −$97.0M | $242.0M |
| Capital expenditure | $34.0M | $36.0M | $31.0M | $32.0M | $33.0M | $43.0M | $25.0M | $30.0M |
| Free cash flow | $117.0M | $168.0M | $6.00M | $88.0M | $141.0M | $338.0M | −$122.0M | $212.0M |
| Share buybacks | $135.0M | $75.0M | $161.0M | $286.0M | $203.0M | $200.0M | $125.0M | $200.0M |
From Henry Schein's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. Net margin is our own calculation from those reported figures (net income ÷ revenue); it is left blank where revenue is zero or missing. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
Henry Schein vs the Health Care sector and the S&P 500
Henry Schein's latest reported figures next to the median of the other 59 S&P 500 Health Care companies and of the other 502 S&P 500 companies; each median is taken over the companies with a comparable figure (counts in the footnote). A median is the middle value, not an average, so one very large company does not move it.
| Measure | Henry Schein | Health Care (59 other S&P 500 companies) | S&P 500 (502 other companies) |
|---|---|---|---|
| Revenue growth, latest fiscal year | +4.0% | +7.2% | +7.0% |
| Net margin, latest fiscal year | 3.0% | 13.1% | 13.0% |
| Share price change, 1 year | +31.3% | +19.8% | +5.6% |
Henry Schein: fiscal year ended December 2025, from its 10-K and 10-Q filings with the SEC. Medians computed October 20, 2026 from each company's latest annual filing (fiscal years ending between July 2025 and September 2026) and our price archive. Prices for every company, Henry Schein included, are the last regular-session prices of October 19, 2026; the 1-year change compares that price with each company's last close on or before October 20, 2025. Net margin and price change are our calculations from reported figures. Each median counts only the companies with a comparable figure (sector / S&P 500): revenue growth 59/496, net margin 59/496, 1-year price change 59/490; the reasons below can overlap. 12 are left out of the price figure because our archive holds no comparable close for them. The S&P 500 price figure is the middle company's change, not the index's return.
About Henry Schein
Henry Schein, Inc. is an American distributor of health care products and services, with operations in 33 countries and territories. It is the world's largest provider of health care solutions to office-based dental and medical practitioners.
Source: Wikipedia — Henry Schein
- Headquarters
- Melville, New York From SEC filings, Oct 2026
Recent News (7)
-
Growth Trajectory and Attractive Valuations Support Henry Schein’s (HSIC) Bullish Thesis
Growth Trajectory and Attractive Valuations Support Henry Schein’s (HSIC) Bullish Thesis
-
What Are Wall Street Analysts' Target Price for Henry Schein Stock? What Are Wall Street Analysts' Target Price for Henry Schein Stock? Barchart.com
-
Henry Schein (HSIC) Q2 2026 Earnings Call Transcript
Henry Schein (HSIC) Q2 2026 Earnings Call Transcript
-
Henry Schein, Inc. Q2 2026 Earnings Call Summary Henry Schein, Inc. Q2 2026 Earnings Call Summary
-
Henry Schein Q2 Earnings Call Highlights Henry Schein Q2 Earnings Call Highlights
-
Henry Schein removes 3 longtime execs in leadership shakeup Henry Schein removes 3 longtime execs in leadership shakeup
-
Why is Henry Schein stock sliding today?
Why is Henry Schein stock sliding today?
More Health Care stocks
- EW Edwards Lifesciences
- GEHC GE HealthCare
- GILD Gilead Sciences
- HCA HCA Healthcare
- HUM Humana
- IDXX Idexx Laboratories
- ILMN Illumina
- INCY Incyte